These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 16267021)

  • 1. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.
    Abrams SL; Ruvolo PP; Ruvolo VR; Ligresti G; Martelli AM; Cocco L; Ratti S; Tafuri A; Steelman LS; Candido S; Libra M; McCubrey JA
    Oncotarget; 2017 Sep; 8(44):76525-76557. PubMed ID: 29100331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
    Hu Z; Slayton WB
    Front Oncol; 2014; 4():112. PubMed ID: 24860788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele.
    Wang Z; Feng Y; Bardeesy N; Wong KK; Liu XY; Ji H
    PLoS One; 2012; 7(5):e37308. PubMed ID: 22606359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered dendritic cell phenotype in response to Leishmania amazonensis amastigote infection is mediated by MAP kinase, ERK.
    Boggiatto PM; Jie F; Ghosh M; Gibson-Corley KN; Ramer-Tait AE; Jones DE; Petersen CA
    Am J Pathol; 2009 May; 174(5):1818-26. PubMed ID: 19349356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
    Chang JS; Santhanam R; Trotta R; Neviani P; Eiring AM; Briercheck E; Ronchetti M; Roy DC; Calabretta B; Caligiuri MA; Perrotti D
    Blood; 2007 Aug; 110(3):994-1003. PubMed ID: 17475908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module.
    Wang X; Studzinski GP
    J Cell Physiol; 2006 Nov; 209(2):253-60. PubMed ID: 16883571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.
    Kornblau SM; Womble M; Qiu YH; Jackson CE; Chen W; Konopleva M; Estey EH; Andreeff M
    Blood; 2006 Oct; 108(7):2358-65. PubMed ID: 16763210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
    Konopleva M; Shi Y; Steelman LS; Shelton JG; Munsell M; Marini F; McQueen T; Contractor R; McCubrey JA; Andreeff M
    Cancer Res; 2005 Nov; 65(21):9962-70. PubMed ID: 16267021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism.
    Hoyle PE; Moye PW; Steelman LS; Blalock WL; Franklin RA; Pearce M; Cherwinski H; Bosch E; McMahon M; McCubrey JA
    Leukemia; 2000 Apr; 14(4):642-56. PubMed ID: 10764150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
    Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
    Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.
    McCubrey JA; Shelton JG; Steelman LS; Franklin RA; Sreevalsan T; McMahon M
    Oncogene; 2004 Oct; 23(47):7810-20. PubMed ID: 15361836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
    Bosch E; Cherwinski H; Peterson D; McMahon M
    Oncogene; 1997 Aug; 15(9):1021-33. PubMed ID: 9285556
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.